Page 12 - Eric Lefebvre News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eric lefebvre. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eric Lefebvre Today - Breaking & Trending Today

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of "Buy" from Analysts

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Rating) have earned an average rating of “Buy” from the eleven brokerages that are currently covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have updated their coverage on the stock in […] ....

United States , Eric Lefebvre , Robertw Baird , Bernard Coulie , Cantor Fitzgerald , Blackrock Inc , Pricet Rowe Associates Inc , Pliant Therapeutics Inc , Vanguard Group Inc , Pliant Therapeutics Company Profile , Jennison Associates , Jpmorgan Chase Co , Needham Company , Pliant Therapeutics , Get Rating , Partners Management , Pricet Rowe Associates , Pliant Therapeutics Daily , Nasdaq Plrx ,

Pliant Therapeutics (NASDAQ:PLRX) Price Target Raised to $63.00

Pliant Therapeutics (NASDAQ:PLRX – Get Rating) had its price target lifted by Cantor Fitzgerald from $52.00 to $63.00 in a report released on Monday, The Fly reports. A number of other research analysts have also recently commented on PLRX. JPMorgan Chase & Co. reduced their target price on shares of Pliant Therapeutics from $51.00 to […] ....

United States , Robertw Baird , Mike Ouimette , Eric Lefebvre , Pliant Therapeutics Inc , Quantamental Technologies , Pliant Therapeutics Company Profile , Management Company Inc , Securities Exchange Commission , Cubist Systematic Strategies , Blackstone Inc , Cantor Fitzgerald , Bessemer Group Inc , Jpmorgan Chase Co , Pliant Therapeutics , Get Rating , General Counsel Mike Ouimette , Exchange Commission , Systematic Strategies , Pliant Therapeutics Daily , Nasdaq Plrx , Boost Price Target ,

Pliant Therapeutics (NASDAQ:PLRX) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Get Rating) in a research report released on Thursday, Benzinga reports. Needham & Company LLC currently has a $45.00 price target on the stock. PLRX has been the subject of several other research reports. HC Wainwright reaffirmed a buy rating […] ....

United States , Nova Scotia , Eric Lefebvre , Mike Ouimette , Pliant Therapeutics Inc , Royal Bank , Securities Exchange Commission , Pricet Rowe Associates Inc , Cantor Fitzgerald , Jennison Associates , Needham Company , Vanguard Group Inc , Blackrock Inc , Pliant Therapeutics , Get Rating , Therapeutics Trading Down , General Counsel Mike Ouimette , Exchange Commission , Partners Management , Pricet Rowe Associates , Pliant Therapeutics Daily , Nasdaq Plrx , Reiterated Rating , Needham Company Llc ,

Robert W. Baird Initiates Coverage on Pliant Therapeutics (NASDAQ:PLRX)

Robert W. Baird assumed coverage on shares of Pliant Therapeutics (NASDAQ:PLRX – Get Rating) in a research report sent to investors on Wednesday morning, The Fly reports. The brokerage issued an outperform rating and a $44.00 price target on the stock. Other equities research analysts also recently issued reports about the company. Citigroup cut their […] ....

United States , Stifel Nicolaus , Robertw Baird , Bernard Coulie , Eric Lefebvre , Jpmorgan Chase Co , Quantamental Technologies , Securities Exchange Commission , Management Company Inc , Cubist Systematic Strategies , Bessemer Group Inc , Royal Bank , Blackstone Inc , Pliant Therapeutics Inc , Pliant Therapeutics , Get Rating , Exchange Commission , Systematic Strategies , Pliant Therapeutics Daily , Nasdaq Plrx , Initiated Coverage ,